Consolidated Statements of Comprehensive (Loss) Income - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (3,549,224)	$ (3,547,782)	$ (12,610,857)	$ 25,123,901
Available for sale securities - net unrealized income (loss)	30,103	(28,717)	(643)	(28,717)
Total other comprehensive income (loss)	30,103	(28,717)	(643)	(28,717)
Comprehensive (loss) income	(3,519,121)	(3,576,499)	(12,611,500)	25,095,184
Comprehensive income (loss) attributable to noncontrolling interests	972	(119,342)	(1,711)	(717,665)
Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (3,520,093)	$ (3,457,157)	$ (12,609,789)	$ 25,812,849